What is it prescribed for? Iqirvo,  Approved on June 10, 2024, is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. What is the name of the drug and what does it do? Iqirvo (pronounced eye-KER-vo),...




